Click here to view original web page at www.biopharmadive.com
Sarah Silbiger via Getty Images New documents released Tuesday depict, in greater detail, how staff at the Food and Drug Administration were not in agreement as the agency weighed whether to approve a controversial new treatment for Alzheimer’s disease. For months, it was known that the FDA team responsible […]